First-in-Class KRAS-Degrader Promising in Pancreatic, Lung Cancers

(MedPage Today) -- Setidegrasib showed promising efficacy in patients with previously treated advanced KRAS G12D-mutated pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC), results from a phase I trial suggested. Among...
Source
MedPage Today
Opens original article in a new tab



